Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00873093 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT00873093: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00873093 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 148 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00873093, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
- DRUG vincristine sulfate
- DRUG therapeutic hydrocortisone
- DRUG L-asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00873093
The ClinicalTrials.gov registry entry for NCT00873093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00873093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00873093 about?
NCT00873093 is a clinical study titled "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking som...
What is the current status of trial NCT00873093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2009-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00873093?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), cytarabine (DRUG), vincristine sulfate (DRUG), therapeutic hydrocortisone (DRUG), L-asparaginase (DRUG).
Who is sponsoring clinical trial NCT00873093?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.